

Management

William J. Newell
Chief Executive Officer

Trevor Hallam, Ph.D.
Chief Scientific Officer

Jay Shukert, MBA
Chief Financial Officer

Henry Heinsohn
Vice President
Development and Manufacturing

Lesley Stolz, Ph.D.
Vice President
Business Development

Board of Directors

Leon Chen, Ph.D.
Skyline Ventures

Bryan Lawlis, Ph.D.
Itero Biopharmaceuticals

David Mack, Ph.D.
Alta Partners

William J. Newell
Sutro Biopharma, Inc.

Daniel H. Petree
P2 Partners

Michael Ross, Ph.D.
SV Life Sciences

Armen Shanafelt, Ph.D.
Lilly Ventures

Investors

Alta Partners
Amgen Ventures
Lilly Ventures
Skyline Ventures
SV Life Sciences

About Sutro Biopharma

Sutro Biopharma is a biopharmaceutical company that is developing a new generation of multi-functional antibody drug conjugate therapeutics and bi-functional antibody-based therapeutics for targeted cancer therapies. Sutro's biochemical synthesis technology, which underpins these therapeutics, allows the rapid and systematic exploration of many protein drug variants to identify multiple drug candidates. Our make-test cycle for hundreds of protein variants, including those incorporating non-natural amino acids, takes approximately two weeks. Once identified, production of these protein drug candidates can be rapidly and predictably scaled up.


Sutro is collaborating with select pharmaceutical and biotechnology companies in the development of novel protein therapeutics that cannot be designed, produced, or studied with current technologies. Sutro's technology is based on Stanford Professor James R. Swartz's, Sc.D., patented Open Cell Free Synthesis (OCFS) technology.

Sutro Biopharma was founded in 2003 and has corporate headquarters in South San Francisco, California and a cGMP manufacturing plant in San Carlos, California.

Sutro's Biochemical Protein Synthesis Technology

Sutro Biopharma's scalable biochemical protein synthesis technology platform enables the design and production of protein therapeutics and conjugate molecules that cannot be produced with other technologies. The technology platform unlocks new therapeutic opportunities through a unique synthesis approach and the introduction of site-specific chemical modifications, including non-natural amino acids, to improve therapeutic performance and provide fixed and specific attachment sites for conjugates.

Conventional methods for expressing proteins depend on utilizing living cell lines that originate from bacteria, yeast, insects, plants, or mammals. Currently, cell-based technologies exhibit several limitations in respect to synthesis of proteins, including those with novel chemical modifications, and many biologics can't be developed in these systems.



Sutro's technology has been designed to promote proper folding by optimizing synthesis and the chemical and physical environment. The components of the system have been selected to closely mimic the environment of the cellular folding compartment. In addition, the open architecture of the system easily allows additions of exogenous chemical species as well as catalysts to promote folding in the cases where those additions are needed. On research scale, the system produces gram per liter quantities of proteins in just five hours.

Sutro Biopharma

Sutro's technology enables:

- Rational combinatorial expression optimization of proteins including antibodies
- Rapid make-test cycles of hundreds of variants producing enough protein for activity and specificity assays in a two-week cycle time
- Synthesis of many proteins and families of proteins that are of interest to researchers including those that have been inaccessible using current cellular expression technologies
- Rapid incorporation of a wide variety of non-natural amino acid side chains, leading to true optimization of protein properties in a combinatorial fashion
- Linearly scalable production of hundreds of liters: direct, fast and predictable advancement from bench to GMP production

Antibody Drug Conjugates and Bispecific Antibody-Based Therapeutics

Sutro Biopharma is using its biochemical protein synthesis technology to produce multifunctional antibody drug conjugate therapeutics and bifunctional antibody-based therapeutics for targeted cancer therapies. These therapeutics will significantly extend the clinical impact of current oncology therapeutic approaches, and are beyond what can be envisioned with current (cell-based) expression technologies. The technology allows for the rapid and systematic exploration of many protein drug variants to identify drug candidates. The Company's make-test cycle for hundreds of protein variants, including those incorporating non-natural amino acids, takes approximately two weeks. This fast make-test cycle provides opportunities for candidate optimization across multiple desirable properties that previously has been difficult or impossible to achieve with cell-based systems. Case studies have provided optimization of warhead location and conjugation in as little as 8 weeks. Once a candidate is identified for further testing, production to larger quantities, including cGMP quality protein, is rapid and predictable. Sutro has the capabilities to produce these proteins in-house providing flexibility and rapidity in data collection and progression of therapeutic programs.

Sutro Biopharma's Pipeline

Sutro Biopharma is currently developing several therapeutic proteins with its biochemical protein synthesis platform. Sutro's lead products are antibody drug conjugates and bispecific antigen binding molecules.

Partnering with Sutro Biopharma

Partners have the opportunity to collaborate with Sutro Biopharma on the company's developing pipeline, or to pursue new drug programs using Sutro's Biochemical Protein Synthesis technology to create novel therapeutics. For information about partnering opportunities contact Lesley Stolz: lstolz@sutro.bio.com

